Abstract
The role of α1A-adrenoceptors in the regulation of opioid secretion from the adrenal glands of streptozotocin-induced diabetic rats (STZ-diabetic rats) was examined in an attempt to determine the mechanism of plasma glucose-lowering action of caffeic acid. In agreement with a previous report, we showed that caffeic acid produced a dose-dependent lowering of the plasma glucose concentration in STZ-diabetic rats along with an increase of plasma β-endorphin-like immunoreactivity (BER). These actions of caffeic acid were abolished by pretreatment with WB 4101 or RS 17 056 at doses sufficient to block α1A-adrenoceptors. In addition, naloxone and naloxonazine at doses effective for blocking opioid µ-receptors abolished the plasma glucose-lowering action of caffeic acid. Also, unlike that in wild-type diabetic mice, caffeic acid failed to produce a plasma glucose lowering effect in opioid µ-receptor knockout diabetic mice. We observed that caffeic acid could enhance BER release from isolated rat adrenal medulla in a concentration-dependent manner; inhibitors of α1A-adrenoceptors such as WB 4101 and RS 1705 abolished this action. Investigations of the signal pathways further supported that activation of α1A-adrenoceptor is responsible for the stimulatory effect of caffeic acid on BER secretion from the adrenal medulla. In the presence of U73312, a specific inhibitor of phospholipase C, the caffeic acid-induced increase of BER was reduced in a concentration-dependent manner, but it was not affected by U73343, the negative control of U73312. Chelerythrine and GF 109203X also diminished the action of caffeic acid at concentrations sufficient for inhibiting protein kinase C. Moreover, bilateral adrenalectomy in STZ-diabetic rats resulted in the loss of this plasma glucose-lowering effect of caffeic acid, and there was no increase in plasma BER with caffeic acid. Therefore, β-endorphin release from the adrenal gland appears to be responsible for the lowering of plasma glucose in STZ-diabetic rats induced by caffeic acid, through the activation of α1A-adrenoceptors.
Key words
Adrenal medulla - α1A-Adrenoceptor - β-Endorphin-like immunoreactivity - Caffeic acid - Phospholipase C - Protein kinase C
References
-
1
Akil H, Watson S J, Young E, Lewis M E, Khachaturian H, Walker J M.
Endogenous opioid: biology and function.
Annu Rev Neurosci.
1984;
7
223-255
-
2 Udenfriend S, Meienhofer J (Eds.). 1984 The peptide, Vo1 6, opioid peptides: biology, chemistry, and genetics. New York; Academic Press
-
3
Liu I M, Niu C S, Chi T C, Kuo D H, Cheng J T.
Investigations of the mechanism of the reduction of plasma glucose by cold-stress in streptozotocin-induced diabetic rats.
Neurosci.
1999;
92
1137-1142
-
4
Cheng J T, Liu I M, Tzeng T F, Tsai C C, Lai T Y.
Plasma glucose lowering effect of β-endorphin in streptozotocin-induced diabetic rats.
Horm Metab Res.
2002;
34
570-576
-
5
Furuta H.
Direct evidence of alpha-adrenoceptor binding in rat and human adrenal glands. Nippon.
Hinyokika Gakkai Zasshi.
1990;
81
161-169
-
6
Wikberg-Matsson A, Wikberg J E, Uhlen S.
Characterization of alpha1-adrenoceptor subtypes in the pigs.
Eur J Pharmacol.
1998;
347
301-309
-
7
Ilcol Y O, Gurun M S, Taga Y, Ulus I H.
Intraperitoneal administration of choline increases serum glucose in rat: involvement of the sympathoadrenal system.
Horm Meta Res.
2002;
34
341-347
-
8
Cheng J T, Liu I M, Kuo D H, Lin M T.
Stimulatory effect of phenylephrine on the secretion of β-endorphin from rat adrenal medulla in vitro.
.
Auton Neurosci Basic & Clinic.
2001;
93
31-35
-
9 Cai J F. 1995 Advanced textbook on traditional Chinese medicine and pharmacology, Vol. 2. Beijing; New World Press pp. 29-30
-
10
Nardini M, D'Aquino M, Tomassi G, Gentili V, di Felice M, Scaccini C.
Inhibition of human low-density lipoprotein oxidation by caffeic acid and other hydroxycinnamic acid derivatives.
Free Radic Biol Med.
1995;
19
541-552
-
11
Hsu F L, Chen Y C, Cheng J T.
Caffeic acid as active principle from the fruit of Xanthium strumarium to lower plasma glucose in diabetic rats.
Planta Med.
2000;
66
228-230
-
12
Cheng J T, Liu I M.
Stimulatory effect of caffeic acid on α1A-adrenoceptors to increase glucose uptake into cultured C2C12 cells.
Naunyn-Schmiedebergs Arch Pharmacol.
2000;
362
122-127
-
13
Loh H H, Liu H C, Cavalli A, Yang W, Chen Y F, Wei L N.
Opioid µ receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality.
Mol Brain Res.
1998;
54
321-326
-
14
Liu I M, Chi T C, Shiao G C, Lin M T, Cheng J T.
Loss of plasma glucose lowering response to cold stress in opioid mu-receptor knock-out diabetic mice.
Neurosci Lett.
2001;
307
81-84
-
15
Cheng J T, Liu I M, Chi T C, Tzeng T F.
Release of β-endorphin by protaglandin E2 to lower plasma glucose in streptozotocin-induced diabetic rats.
Horm Metab Res.
2001;
33
439-443
-
16
Vargo T, Rossier J, Minick S, Ling N, Rivier C, Vale W, Bloom F.
β-Endorphin and adrenal corticotropin are secreted concomitantly by the pituitary gland.
Science.
1977;
197
1367-1369
-
17
Hieble J P, Bylund D B, Clarke D E, Eikenburg D C, Langer S Z, Lefkowitz R J, Minneman K P, Ruffolo R R.
X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol.
Rev.
1995;
47
267-270
-
18
Zhong H, Minneman K P.
α1-Adrenoceptor subtypes.
Eur J Pharmacol.
1999;
375
261-276
-
19
Goldstein A.
Binding selectivity profiles for ligands of multiple receptor types: focus on opioid receptors.
Trends Pharmacol Sci.
1987;
8
456-459
-
20
Pasternak G W.
Pharmacological mechanisms of opioid analgesics.
Clin Neuropharmacol.
1993;
16
1-18
-
21
Martin W R.
Opioid antagonists.
Pharmacol Rev.
1967;
19
463-521
-
22
Ling G SF, Simantov R, Clark J A, Pasternak G W.
Naloxonazine actions in vivo.
Eur J Pharmacol.
1986;
129
33-38
-
23
Cheng J T, Liu I M, Chi T C, Tzeng T F, Lu F H, Chang C J.
Plasma glucose lowering effect of tramadol in streptozotocin-induced diabetic rats.
Diabetes.
2001;
50
2815-2821
-
24
Liu I M, Chi T C, Chen Y C, Lu F H, Cheng J T.
Activation of opioid µ-receptor by loperamide to lower plasma glucose in streptozotocin-induced diabetic rats.
Neurosci Lett.
1999;
265
183-186
-
25
Minneman K P, Han C, Abel P W.
Comparison of α1-adrenergic receptor subtypes distinguished by chlorethylclonidine and WB 4101.
Mol Pharmacol.
1988;
33
509-514
-
26
Marshall I, Burt R P, Green G M, Hussain M B, Chapple C R.
Different subtypes of alpha 1A-adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17 053.
Br J Pharmacol.
1996;
119
407-415
-
27
Arefolov V A, Dmitriev A D, Tennov A V, Val'dman A V.
Detection of the pro-opiomelanocortin peptide fragments - beta-endorphin and ACTH-in the adrenals of rats and mice by immunohistochemistry.
Biull Eksp Biol Med.
1986;
101
445-447
-
28
Mitsuma T, Nogimori T, Sun D H, Chaya M.
Thyrotropin-releasing hormone reduces the plasma levels of beta-endorphin-like immunoreactivity in rats.
Exp Clin Endocrinol.
1987;
89
55-60
-
29
Vatta M S, Presas M F, Bianciotti G, Rodriguez-Fermepin M, Ambros R, Fernandez B E.
B and C types natriuretic peptides modify norepinephrine uptake and release in the rat adrenal medulla.
Peptides.
1997;
18
1483-1489
-
30
Koenig J I, Meltzer H Y, Devane G D, Gudelsky G A.
The concentration of arginine vasopressin in pituitary stalk plasma of the rat after adrenalectomy or morphine.
Endocrinology.
1986;
118
2534-2539
-
31
Stratakis C A, Miller W R, Severin E, Chin K V, Bertherat J, Amieux P S, Eng C, Kammer G M, Dumont J E, Tortora G, Beaven M A, Puck T T, Jan d e, Weistein L S, Cho-Chung Y S.
Protein-kinase A and human disease: the core of cAMP-dependent signaling in health and disease.
Horm Metab Res.
2002;
34
169-175
-
32
Smallridge R C, Kiang J G, Gist I D, Fein H G, Gallowat R J.
U-73122, an aminosteroid phospholipase C antagonist, noncompetitively inhibits thyrotropin-releasing hormone effects in GH3 rat pituitary cell.
Endocrinology.
1992;
131
1883-1888
-
33
Muto Y, Nagao T, Urushidani T.
The putative phospholipase C inhibitor U73122 and its negative control, U73343, elicit unexpected effects on the rabbit parietal cell.
J Pharmac Exp Ther.
1997;
282
1379-1388
-
34
de Moel M P, van de Put F H, Vermegen T M, de Pont J H, Willems P H.
Effect of the aminosteroid, U73122, on Ca2+ uptake and release properties of rat liver microsomes.
Eur J Biochem.
1995;
234
626-631
-
35
Wang J P, Hsu M F, Kuo S C.
Inhibition by abruquinone A of phosphoinositide-specific phospholipase C activation in rat neutrophils.
Eur J Pharmacol.
1997;
319
131-136
-
36
Herbert J M, Augereau J M, Gleye J, Maffrand J P.
Chelerythrine is a potent and specific inhibitor of protein kinase C.
Biochem Biophys Res Commun.
1990;
172
993-999
-
37
Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, Baudent V, Boissin P, Boursier E, Loriolle F, Duhamel L, Charon D, Kirilovsky J.
The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C.
J Biol Chem.
1991;
266
15 771-15 781
Prof. J. T. Cheng
Department of Pharmacology · College of Medicine · National Cheng Kung University
Tainan City · Taiwan 70101 · R.O.C. ·
Telefon: +886(6)2372706
Fax: +886(6)2386548
eMail: jtcheng@mail.ncku.edu.tw
